428 related articles for article (PubMed ID: 27440267)
1. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
2. Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade.
Zheng J; Sha Y; Roof L; Foreman O; Lazarchick J; Venkta JK; Kozlowski C; Gasparetto C; Chao N; Ebens A; Hu J; Kang Y
Cancer Lett; 2019 Jan; 440-441():1-10. PubMed ID: 30312729
[TBL] [Abstract][Full Text] [Related]
3. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma.
Raab MS; Thomas SK; Ocio EM; Guenther A; Goh YT; Talpaz M; Hohmann N; Zhao S; Xiang F; Simon C; Vanasse KG; Kumar SK
Leukemia; 2019 Dec; 33(12):2924-2933. PubMed ID: 31092894
[TBL] [Abstract][Full Text] [Related]
4. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
7. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
Peters TL; Li L; Tula-Sanchez AA; Pongtornpipat P; Schatz JH
Oncotarget; 2016 Sep; 7(39):63362-63373. PubMed ID: 27556513
[TBL] [Abstract][Full Text] [Related]
8. Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma.
Paíno T; González-Méndez L; San-Segundo L; Corchete LA; Hernández-García S; Díaz-Tejedor A; Algarín EM; Mogollón P; Martín-Sánchez M; Gutiérrez NC; Mateos MV; Garayoa M; Ocio EM
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987735
[TBL] [Abstract][Full Text] [Related]
9. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
[TBL] [Abstract][Full Text] [Related]
10. Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.
Liang SB; Yang XZ; Trieu Y; Li Z; Zive J; Leung-Hagesteijn C; Wei E; Zozulya S; Coss CC; Dalton JT; Fantus IG; Trudel S
Clin Cancer Res; 2011 Jul; 17(14):4693-704. PubMed ID: 21632854
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
12. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
13. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
14. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
[TBL] [Abstract][Full Text] [Related]
15. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
[TBL] [Abstract][Full Text] [Related]
17. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
[TBL] [Abstract][Full Text] [Related]
18. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
19. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
20. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
